NEW YORK – Dutch biopharmaceutical company Byondis (formerly Synthon Biopharmaceuticals) said on Monday that Quantum Leap, the company sponsoring the ongoing Phase II/III I-SPY 2 trial for subgroups of women with breast cancer, has selected Byondis' antibody-drug conjugate SYD985 for inclusion in a new treatment arm of the study.